文献速递前列腺癌

达罗他胺与恩扎卢胺在无症状或轻微症状转移性去势抵抗性前列腺癌男性中的随机、开放标签、交叉2期试验:ODENZA研究的患者偏好与认知功能

A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
PubMed 文献 · Eur Urol · 2023-06-02

ODENZA是一项前瞻性、随机、多中心、交叉2期试验,评估无症状或轻微症状转移性去势抵抗性前列腺癌(mCRPC)男性对达罗他胺与恩扎卢胺的偏好。249例患者随机接受达罗他胺1200 mg/d或恩扎卢胺160 mg/d治疗12周后交叉。在200例符合主要终点评估标准的患者中,选择达罗他胺、恩扎卢胺和无偏好者分别为97例(49%)、80例(40%)和23例(12%)(p=0.92)。达罗他胺在情景记忆和疲劳方面优于恩扎卢胺。

要点

  • 在可评估患者中,选择达罗他胺、恩扎卢胺和无偏好者分别为49%、40%和12%,组间无显著差异(p=0.92)。
  • 达罗他胺在情景记忆(新信息获取LS均值差2.2,效应量0.5;延迟回忆LS均值差0.7,效应量0.3)和疲劳方面优于恩扎卢胺。
  • 达罗他胺与恩扎卢胺在抑郁、癫痫发作和跌倒方面无差异。

核心结论

  • 研究未显示两种治疗之间存在偏好差异。
  • 在mCRPC男性中,与恩扎卢胺相比,达罗他胺与情景记忆的临床意义获益和更少疲劳相关。

研究设计与样本

  • ODENZA是一项前瞻性、随机、多中心、交叉2期试验。
  • 患者按1:1随机接受达罗他胺1200 mg/d治疗12周后序贯恩扎卢胺160 mg/d治疗12周,或反向序贯;若无癌症进展,则给予第二种治疗。
  • 共249例患者随机,中位年龄72岁。
  • 主要终点为通过偏好问卷评估的患者对两种药物的偏好(p值采用Prescott检验计算)。
  • 第24周后,患者进入扩展期,接受其首选治疗直至进展或毒性。

主要发现

  • 在200例符合主要终点评估预设标准的患者中,97例(49% [41; 56])选择达罗他胺,80例(40% [33; 47])选择恩扎卢胺,23例(12% [7; 16])无偏好(p=0.92)。
  • 影响患者选择的主要标准为疲劳减轻、给药更方便和更好的生活质量。
  • 达罗他胺在新信息获取方面显示情景记忆的中度获益(最小二乘[LS]均值差=2.2,效应量=0.5),在短暂延迟后回忆该信息方面(LS均值差=0.7,效应量=0.3)。
  • 采用简明疲劳量表问卷,患者报告恩扎卢胺的疲劳(3.3 [3.0; 3.6])高于达罗他胺(2.7 [2.4; 3.0])。
  • 在抑郁、癫痫发作和跌倒方面无差异。

关键数值与推荐

  • 在200例可评估患者中,选择达罗他胺97例(49% [41; 56])、恩扎卢胺80例(40% [33; 47])、无偏好23例(12% [7; 16]),p=0.92。
  • 达罗他胺对比恩扎卢胺:情景记忆新信息获取LS均值差=2.2,效应量=0.5;延迟回忆LS均值差=0.7,效应量=0.3。
  • 简明疲劳量表评分:恩扎卢胺3.3 [3.0; 3.6] vs 达罗他胺2.7 [2.4; 3.0]。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Darolutamide and enzalutamide are second-generation androgen receptor inhibitors with activity in men with castrate-resistant prostate cancer (CRPC) and different toxicity profiles. OBJECTIVE: ODENZA is a prospective, randomized, multicenter, cross-over, phase 2 trial designed to assess preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic CRPC (mCRPC). DESIGN, SETTING, AND PARTICIPANTS: Patients were randomized 1:1 to receive either darolutamide 1200 mg/d for 12 wk followed by enzalutamide 160 mg/d for 12 wk or enzalutamide followed by darolutamide. In both arms, the second treatment was given in absence of cancer progression. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was patient preference between the two drugs, as assessed by a preference questionnaire (p value calculated with the Prescott test). After week 24, patients entered an extension period during which they received their preferred treatment until progression or toxicity. The main secondary objectives included reasons for patient preference, response at week 12, tolerance of each drug, and measurement compared with baseline of cognitive outcomes assessed using tablet questionnaires. RESULTS AND LIMITATIONS: Overall, 249 patients, with a median age of 72 yr, were randomized. Among the 200 patients who fulfilled the preplanned criteria for the evaluation of the primary endpoint of preference, 97 (49% [41; 56]), 80 (40% [33; 47]), and 23 (12% [7; 16]) chose darolutamide, chose enzalutamide, and had no preference, respectively (p = 0.92). Reduced fatigue, easier administration, and better quality of life were the main criteria that influenced patient choice. A moderate benefit in episodic memory from darolutamide was observed for the acquisition of new information (least square [LS] means difference = 2.2, effect size = 0.5) and for the recall of that information after a brief delay (LS means difference = 0.7, effect size = 0.3). Using the Brief Fatigue Inventory questionnaire, patients reported greater fatigue with enzalutamide (3.3 [3.0; 3.6]) than with darolutamide (2.7 [2.4; 3.0]). There was no difference in terms of depression, seizures, and falls. CONCLUSIONS: The study did not show a difference in preference between the two treatments. In men with mCRPC, darolutamide was associated with a clinically meaningful benefit in episodic memory and less fatigue compared with enzalutamide. PATIENT SUMMARY: Preference between darolutamide and enzalutamide was well balanced in men with castrate-resistant prostate cancer. Darolutamide was associated with a significant benefit in verbal learning and less fatigue compared with enzalutamide.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Colomba E, Jonas SF, Eymard JC, et al. A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA. Eur Urol. 2023. PMID: 37271630. doi:10.1016/j.eururo.2023.05.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。